Juul will suspend sales of most flavored vapes in retail stores and halt its social media promotions. The company’s announcement preempted an FDA ban, expected this week, on flavored e-cigarette sales in stores like pharmacies and gas stations. (New York Times)

Google’s new health unit is set to absorb the health division of DeepMind, Alphabet’s AI research group. DeepMind’s main health project uses AI to help doctors spot kidney failure. However, some privacy experts worry that identifiable patient information could be shared with Google once DeepMind is integrated into the company. (CNBC)

Healthcare technology company Indegene launched a digital agency, iON. It is led by Jamie Peck, who was VP of multichannel marketing and product commercialization. The agency will work with Indegene’s pharma clients with creative, technology, and digital strategy services. (PR Newswire)

A study found Tylenol’s rapid-release capsules are slower than cheaper tablets. A J&J spokesperson said the rapid-release claim was only tested against other gelcaps, not uncoated tablets. Yet the findings have raised concerns about how marketing could mislead and push consumers to spend more. (Washington Post)

Merck cancer treatment Keytruda succeeded in a late-stage esophageal cancer trial. The treatment was found to increase survival rates compared to traditional chemotherapy. Keytruda has been proven to be more effective than chemo in fighting six types of cancer. (Reuters)